Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.
Sybil Mead
Advertisement
Sybil Mead is vice president of market access at Sperix Global Insights.
Articles by Sybil Mead
Advertisement
Latest Updated Articles
Advertisement
Advertisement